Zoetis is a high-quality animal health business with 68% return on equity, 28% net margins, and a 3-for-4 earnings beat streak — but an extraordinary put-to-call ratio of 18.50, a confirmed death-cross technical pattern, and heavy concentration in companion animal products (70%) create a profile where the long-term quality case is strong but the near-term setup is unusually risky.
Thesis pillars
- Top Decile Quality Metrics→Stable
- Companion Animal Concentration 70pct↓Deteriorating
- Extreme Put Call Ratio Warning↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 12, 2026· older than 90 days
Zoetis Inc. (ZTS) Stock Analysis
Recovery setup
Healthcare · Drug Manufacturers - Specialty & Generic
Hold if already holding. Not a fresh buy at $82.99, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%).
Zoetis discovers and commercializes animal health medicines, vaccines, and diagnostics across eight species, organized into U.S. ($5,097 million, 54% of 2025 revenue) and International ($4,254 million, 45%) segments. Companion animal products — led by Simparica/Trio, Apoquel,... Read more
Hold if already holding. Not a fresh buy at $82.99, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%). Chart setup: Death cross but MACD improving, RSI 73. Downgraded from BUY WAIT — price $82.99 vs the analyst target $76.89: -7.3% upside; No upside left. Score 5.4/10, moderate confidence.
Passes 6/10 gates (positive momentum, clean insider activity, positive momentum, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 1d<=7d. Suitability: speculative.
About Zoetis Inc.
About Zoetis Inc.
Zoetis generated $5,097 million in U.S. revenue and $4,254 million in international revenue during fiscal 2025, representing 54% and 45% of consolidated sales respectively, with companion animal products contributing approximately 70% of total revenue. The five top-selling product lines — Simparica/Simparica Trio, Apoquel/Apoquel Chewable, Cytopoint, Librela, and the ceftiofur line — contributed 42% of 2025 revenue collectively, and the top ten product lines reached 57%. The company directly markets products in approximately 45 countries, with sales in more than 100 countries overall.
Zoetis sells through veterinarians and livestock producers via direct sales forces, with no single distributor named as dominant in the filing. Companion animal revenue, at 70% of total sales, is concentrated in three therapeutic categories: dermatology (Apoquel, Cytopoint), parasiticides (Simparica/Simparica Trio), and pain management (Librela, Solensia). Livestock revenue, at approximately 29% of total, includes $713 million in antibacterial sales in 2025, subject to use restrictions across the U.S., EU, U.K., China, and Vietnam. Multiple companies have launched generics against Rimadyl chewable and Draxxin; U.S. sales of Draxxin fell 66% since generic entry and Rimadyl chewable fell 39%, illustrating the loss-of-exclusivity risk embedded in the livestock portfolio. The company does not rely on a single distributor and markets products through veterinary practices, wholesalers, and internet-based retailers.
Show full overview
The top-five product line dependency represents the most concentrated earnings exposure: Simparica/Simparica Trio at 16% of 2025 revenue and Apoquel/Apoquel Chewable at 12% together account for 28%, with Cytopoint, Librela, and the ceftiofur line bringing the top-five total to 42%. The 10-K identifies safety concerns, manufacturing disruption, regulatory proceedings, or competing product introductions as risks that could have a more significant impact to results of operations for these specific lines. Any single adverse event in this product tier — safety labeling change, supply disruption, or accelerated generic entry — could materially shift reported earnings, making these franchises both the core revenue pillar and the primary concentration risk.
See also: Healthcare · Drug Manufacturers - Specialty & Generic
From Zoetis Inc.'s most recent 10-K filing, extracted June 16, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Zoetis Inc.
Latest news
- NEWS Earnings to watch: Zoetis (ZTS) reports Q3 results tomorrow - TradingView — TradingView Nov 4, 2026 neutral
- NEWS Zoetis (ZTS) Stock Looks Reasonable Despite Its 61% Five Year Slide - Simply Wall St — Simply Wall St Oct 28, 2026 neutral
- NEWS Zoetis (ZTS) Stock May Be Undervalued After FDA Approval News - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Zoetis (ZTS) Won FDA Approval For A New Single Dose Dog Antibiotic - Yahoo Finance — Yahoo Finance Oct 28, 2026 positive
- NEWS Are AT&T and Zoetis Unjustly Punished as Rising Rates Cool Dividend Stock Appeal? - NAI500 — NAI500 Oct 28, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-04T11:54:39Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States54%10-K Item 1: 'United States (U.S.) with revenue of $5,097 million, or 54% of total revenue for the year ended December 31, 2025'
- HIGHProductcompanion animal products70%10-K Item 1: 'Companion animal products represented approximately 70% of our revenue for the year ended December 31, 2025'
- MEDIUMProducttop five product lines42%10-K Item 1A: 'our five top-selling products and product lines...contributed approximately 42% of our revenue in 2025'
Material Events(8-K, last 90d)
- 2026-05-22Item 5.02LOWLouise M. Parent retired from the Zoetis Board of Directors effective May 20, 2026, prior to the 2026 Annual Meeting, in accordance with the company's director retirement policy. No reason cited beyond policy compliance. No successor named.SEC filing →
- 2026-05-22Item 5.07LOWZoetis held its 2026 Annual Meeting on May 20, 2026 with 379,034,516 shares present (90.13% of voting power). Shareholders voted on five proposals as described in the April 8, 2026 proxy statement. Routine AGM; no contested matters noted.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Revenue shrinking — -0.2% YoY. Growth thesis broken unless recovery story develops.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $82.99, but acceptable to hold if already in. Reasons: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%). Chart setup: Death cross but MACD improving, RSI 73. Downgraded from BUY WAIT — price $82.99 vs the analyst target $76.89: -7.3% upside; No upside left. Analyst target $76.89 reached (−7.3%), stop $76.75 (−8.1%), A.R:R -0.5:1. Score 5.4/10, moderate confidence.
Analyst target $76.89 reached (−7.3% from $82.99); no take-profit level is published. Analyst target $76.89 reached (−7.3%), stop $76.75 (−8.1%), A.R:R -0.5:1. Stop-loss: $76.75.
Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%); Analyst target reached - limited upside remaining.
Zoetis Inc. trades at a P/E of 13.7 (forward 13.0). TrendMatrix value score: 6.4/10. Verdict: Hold.
22 analysts rate ZTS, with a consensus score of 3.5/5. 13 analysts publish price targets averaging $88.
What does Zoetis Inc. do?Zoetis discovers and commercializes animal health medicines, vaccines, and diagnostics across eight species, organized...
Zoetis discovers and commercializes animal health medicines, vaccines, and diagnostics across eight species, organized into U.S. ($5,097 million, 54% of 2025 revenue) and International ($4,254 million, 45%) segments. Companion animal products — led by Simparica/Trio, Apoquel, Cytopoint, and Librela — drove approximately 70% of 2025 revenue, with the five top-selling lines collectively accounting for 42%.